Format

Send to

Choose Destination
See comment in PubMed Commons below
Transplant Proc. 2008 May;40(4):1207-11. doi: 10.1016/j.transproceed.2008.03.118.

Sepsis in transplanted patients: beyond antibiotic therapy.

Author information

1
Università degli Studi Milano Bicocca, Dipartimento di Medicina Sperimentale, Azienda Ospedaliera San Gerardo di Monza, Monza, Italy.

Abstract

Severe sepsis in transplant recipients results in an extremely high morbidity mortality rate. Microvascular alterations play an important role in the development of sepsis-induced organ dysfunction. Therefore, addition to standard treatment, which we divide into prophylaxis, preemptive therapy, and therapy, activated protein C (or Drotrecogin Alpha Activated [DAA]) represents a radically new approach for these patients. Herein we have reported the first trials evaluating the use of DAA in transplant recipients experiencing sepsis. Comparable trials in humans are still not available for the other coagulation, inhibitor antithrombin. We also report clinical trials discussing whether hyperimmune products reduce the infection rate during myelosuppression, but further trials are requested for the feasible evaluation of these products.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center